EXAS

EXAS is currently a 'Special Situation' Merger Arbitrage play, effectively pinned just below the $105.00/share acquisition offer from Abbott Laboratories (ABT). The 'Quiet Storm' signal and bond-like 2.9% volatility are not organic technicals but structural artifacts of the deal peg ahead of the shareholder vote scheduled for tomorrow (Feb 20, 2026). While the broad market is rattled by the 'Caution' regime (Trump/Iran headlines), EXAS's relative strength (+0.9% vs SPY) confirms that the deal spread is acting as a defensive haven, absorbing the macro shock.